Le-Meridian Al Madinah Jan. 26-27 2018

12th  Middle East Best of San Antonio Breast Cancer Symposium

About the event

The 12th Middle East Best of SABCS allows professionals, who are unable to travel to San Antonio, the opportunity to experience and discuss the research and advances with colleagues and key opinion leaders.  Hence, the attendees to the 12th Middle East Best of SABCS program will receive the most current information on breast cancer research presented in the original format delivered at the meeting in San Antonio in December 2017. Moreover, you will learn of the current advances in breast cancer research that are changing clinical practice for the benefit of patients.
Principal subject areas of the 12th Middle East Best of SABCS program include:

  • Cancer Immunology 101.
  • Triple Negative Breast Cancer.
  • Breast Cancer Prevention: Consolidating Gains and Charting New Directions.
  • Follow-up Care and Lifestyle Recommendations to Improve Outcomes.
  • HER2+ Breast Cancer and,
  • Assessment and Treatment of Older Adults with Breast Cancer

Chairman Message

Omalkhair Abulkhair, MD

The Organizing Committee of the 12th Middle East Best of San Antonio Breast Cancer Symposium and the Saudi Cancer Foundation welcome you to 12th Middle East Best of SABCS™. SABCS™ is now in its 40th year, is the premier conference for basic, translational, and clinical cancer research professionals. It is well known for presenting the latest breast cancer data from all over the world. The Best of SABCS™ allows professionals, who are unable to travel to San Antonio, the opportunity to experience and discuss the research and advances with colleagues and key opinion leaders. Attendees to the Best of SABCS™ program will receive the most current information on breast cancer research presented in the original format delivered at the meeting in San Antonio in December 2017. You will learn of the current advances in breast cancer research that are changing clinical practice for the benefit of patients.

Sincerely,

Omalkhair Abulkhair, MD

Chairman of 12th Middle East Best of SABCS™ “

DOWNLOAD BROCHURE
Dr Abulkheir pic
committee

MESABCS 2018 COMMITTEES

MEET THE 2018 COMMITTEE
Chairman: Dr. Omalkhair Abulkhair
Co-Chairman: Dr. Ahmed Saadeddin
 
Members:
Dr. Sharif Kullab
Dr. Abdulaziz Al Saif
Dr. Mervat Mahrous
Dr. Wael El Melouk
Dr. Salem Al Shehry
Chairman: Dr. Ahmed Saadedin
Co-Chairman: Dr. Omalkhair Abulkhair
 
Members:
Prof. Jean-Marc Nabholtz
Dr. Taher Tweigeri
Dr. Abdulaziz Al Saif
Dr. Yasir Bahadur
Dr. Lobna Sedky
Dr. Heba Zawary
Chairman: Dr. Adel Sayes
Co-Chairman: Dr. Omalkhair Abulkhair
Co-Chairman: Dr. Majed Al Jahel
 
Members:
Donabel Bigtas
Shehab Hashim

Participated Faculties

Faculties of 7 different countries under one roof

At the 12th Best of Middle East San Antonio Breast Cancer Symposium you will get the chance to network with professionals from 7 different countries. Check the list of faculties from the tabs below:

Dr. Hamdy Azim
Dr. Lobna Sedky
Dr. Alaa Kandil
Dr. Nasr Allahloubi
Dr. Maher Aidarous
DrDr. Heba Zawary
Dr. Samir Shehata
Dr. Hassan Jaafar
Dr. Falah Al Khatib
Dr. Sami Al Khatib
Dr. Belal El Hawwari
Dr. Hikmat Abdelrazek
Dr. Sana Al Sukhun
Dr. Mahmoud Al Masri
Dr. Salah Fayaz
(Riyadh – KFSHRC)
Dr. Taher Tweigeri
Dr. Adhar Al Sayed
Dr. Dahish Ajarim
Dr. Essam Murshid
Dr. Osama Al Malik
Dr. Kawthar Soliman
(Riyadh – King Khaled Hospital)
Prof. Jean Marc Nabholtz
Dr. Khaled Saleh
Dr. Abdulaziz Al Saif
(Riyadh – NGHA Jeddah)
Dr. Meteb Foheidi
Dr. Ahmed Al Shehri
Dr. Yasir Bahadur
Dr. Jamal Zekri 
shutterstock_63524988b8

HURRY UP! ABSTRACT SUBMISSION IS NOW OPEN…

Deadline of Abstract Submission is 1st January, 2018

WHO SHOULD ATTEND

Shall I attend?!!

Wonder if this event suites you or not? Here’s a list of those professions that this event was made for. If you are one of them, you will probably make a good use of attending the event.

  • Medical Oncologists

  • Surgeons

  • Radiation Oncologists/ Radiologists

  • Pathologists

  • Oncology Nurses

  • Onco-Genetics

  • Scientists

  • Medical Education & Social Workers

  • Patient Advocates

CONFERENCE AGENDA

Day 1 Agenda

Friday, 26 January 2018

9:00AM

Welcome and Opening Remarks

9:00AM - 9:10AM

Speakers: Dr. Omalkhair Abulkhair, Dr. Maged Algahel

9:10AM

EARLY BREAST CANCER

9:10AM - 10:40AM

Chairpersons: Dr. Huda Abdulkareem, Dr. Jamal Eddin Zekri, Dr. Moustafa Al-Mubarak, Dr. Nasr Allahloubi

09:10am – 09:25am GS1-01. Increasing the dose density of adjuvant chemotherapy by shortening intervals between courses or by sequential drug administration significantly reduces both disease recurrence and breast cancer mortality: an EBCTCG meta-analysis of 21,000 women in 16 randomised trials

Speaker: Dr. Hulayel Alharbi

09:25am – 09:40am GS3-01. A prospective randomized multi-center phase-III trial of additional 2 versus additional 5 years of Anastrozole after initial 5 years of adjuvant endocrine therapy – results from 3,484 postmenopausal women in the ABCSG-16 trial

Speaker: Dr. Shaheenah Dawood

09:40am – 09:55am GS3-04. A randomized phase III study of adjuvant trastuzumab for a duration of 9 weeks versus 1 year, combined with adjuvant taxane-anthracycline chemotherapy, for early HER2-positive breast cancer (the SOLD study)

Speaker: Dr. Heba Zawahry

09:55am – 10:10am GS4-02. Randomized comparison of adjuvant aromatase inhibitor exemestane (E) plus ovarian function suppression (OFS) vs tamoxifen (T) plus OFS in premenopausal women with hormone receptor positive (HR+) early breast cancer (BC): Update of the combined TEXT and SOFT trials

Speaker: Prof. Hesham El Ghazaly

10:10am – 10:25am GS4-01. Pooled analysis of five randomized trials investigating temporary ovarian suppression with gonadotropin-releasing hormone analogs during chemotherapy as a strategy to preserve ovarian function and fertility in premenopausal early breast cancer patients

Speaker: Dr. Medhat Faris

10:25am – 10:40am GS4-03. Randomized comparison of adjuvant tamoxifen (T) plus ovarian function suppression (OFS) versus tamoxifen in premenopausal women with hormone receptor-positive (HR+) early breast cancer (BC): Update of the SOFT trial

Speaker: Dr. Ahmed Abdulfatah Refae

10:40AM

Break

10:40AM - 11:00AM

11:00AM

UPDATE ON BONE HEALTH (SUPPORTED BY AMGEN)

11:00AM - 12:00PM

Chairpersons: Dr. Omalkhair Abulkhair, Dr. Salah Fayaz, Dr. Samir Shehata

11:00am – 11:20am Introduction to bone health

Speaker: Dr. Hamdy Abdel Azim

11:20am – 11:35am GS1-06. Extended adjuvant bisphosphonate treatment over five years in early breast cancer does not improve disease-free and overall survival compared to two years of treatment: Phase III data from the SUCCESS A study

Speaker: Dr. Hamdy Abdel Azim

11:35am – 11:50am Case presentation

Speaker: Dr. Wael Elmelouk

11:50am – 12:00pm Discussion

12:00PM

PRAYER AND LUNCH BREAK

12:00PM - 1:30PM

01:30PM

SURGICAL UPDATE

01:30PM - 02:05PM

Chairpersons: Dr. Abdulaziz A. Alsaif, Dr. Ihab Mohamed Anwar, Dr. Khaled Al-Hagery

01:30pm – 01:50pmIndividualizing management of the axillary nodes

Speaker: Dr. Mahmoud Al Masri

01:50pm – 02:05pm GS5-01. Appropriate margins for breast conserving surgery in patients with early stage breast cancer: A meta-analysis

Speaker: Dr. Osama Malik

02:05PM

ABSTRACT PRESENTATION FROM THE MIDDLE EAST

02:05PM - 02:35PM

Chairpersons : Dr. Ahmed Ali Saadeddin, Dr. Omalkhair Abulkhair, Dr. Huda Abdulkarim

02:05pm – 02:20pm Prognostic significance of androgen receptor expression in estrogen receptor-negative breast cancer

Speaker: Dr. Enas Elkhouly

02:20pm – 02:35pm The efficacy, safety profiles and survival analysis of neoadjuvant chemotherapy ±Trastuzumab in locally advanced breast cancer

Speaker: Dr. Taher Tweigeri

02:35pm

IMMUNO-ONCOLOGY PART 1 (SUPPORTED BY BMS/MSD)

02:35pm - 04:00pm

Chairpersons: Dr. Mohamed Rahal, Dr. Maher Aidarous , Dr. Abdelrahman Alkinj, Dr. Ahlam Duhl

02:35pm – 03:00pm General introduction to immune therapy, current understanding

Speaker: Prof. Jean-marc Nabholtz

03:00pm – 03:15pm Immuno-therapy updates in lung cancer

Speaker: Dr. Hassan Jaffar

03:15am – 03:30am Immuno-therapy updates in bladder cancer

Speaker: Dr. Shawky Bazerbashi

03:30pm – 03:50pm (BMS Satelite Symposium)

Immuno-therapy updates in kidney cancer

Speaker: Dr. Fahad Ibnshamsah

03:50pm – 04:00pm Immuno-therapy updates in colorectal cancer

Speaker: Dr. Ahmed S. Al Shehri

04:00pm

END OF DAY 1

04:00pm -

7:00PM

OPENING CEREMONY & GALA DINNER

7:00PM - 9:00PM

Day 2 Agenda

Saturday, 27 January 2018

9:00AM

ADVANCE AND METASTATIC BREAST CANCER (SUPPORTED BY NOVARTIS & PFIZER) A- Hormonal positive breast cancer

9:00AM - 12:00PM

Chairpersons: Dr. Ahmed Ali Saadeddin, Dr. Dahish Ajarim, Dr. Sami Ahmad Khatib

09:00am – 09:30am Metastatic breast cancer: Endocrine therapy landscape reshaped

Speaker: Dr. Taher AL Tweigeri

09:30am – 09:40am GS2-05. First-line ribociclib vs placebo with goserelin and tamoxifen or a non-steroidal aromatase inhibitor in premenopausal women with hormone receptor-positive, HER2-negative advanced breast cancer: Results from the randomized phase III MONALEESA-7 trial

Speaker: Dr. Majid Al Jahel

09:40am – 09:50am GS2-07. MANTA – A randomized phase II study of fulvestrant in combination with the dual mTOR inhibitor AZD2014 or everolimus or fulvestrant alone in estrogen receptor-positive advanced or metastatic breast cancer

Speaker: Dr. Meteb Al Foheidi

09:50am – 10:05am Efficacy and Safety of Palbociclib Plus Letrozole as First-Line Therapy in Estrogen Receptor–Positive/Human Epidermal Growth Factor Receptor 2–Negative Advanced Breast Cancer: Findings by Geographic Region From PALOMA-2

Speaker: Dr. Esam Murshid

10:05am – 10:15am Palbociclib exposure-response analyses in the treatment of hormone-receptor positive (HR+), human epidermal growth factor receptor 2 negative (HER2-) advanced breast cancer (ABC)

Speaker: Prof. Ezzeldin Ibrahim

10:15am – 10:25am GS6-02. The benefit of abemaciclib in prognostic subgroups: An exploratory analysis of combined data from the MONARCH 2 and 3 studies

Speaker: Dr. Abdullah K. Altwairgi

10:25am – 10:35am Discussion

10:35am – 10:50am Break

10:50am – 11:00am GS3-06. Long-term follow-up of CALGB 40502/NCCTG N063H (Alliance): A randomized phase III trial of weekly paclitaxel (P) compared to weekly nanoparticle albumin bound nab-Paclitaxel (NP) or ixabepilone (IX) +/- bevacizumab as first-line therapy for locally recurrent or metastatic breast cancer (MBC)

Speaker: Dr. Ahmed Al Faraj

11:00am – 11:15am GS3-08. Pathological complete response predicts event-free and distant disease-free survival in the I-SPY2 TRIAL

Speaker: Dr. Sana Al Sukhun

11:15AM

ADVANCE AND METASTATIC BREAST CANCER B-HER2 Over Expression Breast Cancer Cases From Clinic

11:15AM - 12:00PM

Chairpersons: Dr. Omalkhair Abulkhair, Dr. Banu Arun, Dr. Majid Al Jahel

11:15am – 11:30am First line metastatic HER2 over expressed breast cancer

Speaker: Dr. Meteb Al Foheidi

11:30am – 11:45am Second line metastatic HER2 over expressed breast cancer

Speaker: Dr. Ahmed Ali Saadeddin

11:45am – 12:00pm Discussion , Q & A

12:00PM

PRAYER AND LUNCH BREAK

12:00PM - 01:00PM

01:00PM

UPDATE IN PARP INHIBITOR (SUPPORTED BY ASTRA ZENECA)

01:00PM - 02:00PM

Chairpersons: Dr. Taher AL Tweigeri, Dr. Adhar Al-Sayed, Dr. Sharif Kullab

01:00pm – 01:15pm Introduction

Speaker: Dr. Banu Arun

01:15pm – 01:30pm GS4-06. Cancer risks and response to targeted therapy associated with BRCA2variants of uncertain significance

Speaker: Dr. Banu Arun

01:30pm – 01:45pm GS6-07. EMBRACA: A phase 3 trial comparing talazoparib, an oral PARP inhibitor, to physician’s choice of therapy in patients with advanced breast cancer and a germline BRCA mutation

Speaker: Dr. Banu Arun

01:45pm – 02:00pm Discussion

02:00PM

UPDATE IN IMMUNE-ONCOLOGY PART 2 (SUPPORTED BY MSD/BMS)

02:00PM - 03:15PM

Chairpersons: Dr. Ahlam Dohel, Dr. Esam Murshid, Dr. Ahmed Alwabari, Dr Emad Hamada

02:00pm – 02:15pm Immuno-therapy and breast cancer updates, current understanding and future directions

Speaker: Dr. Hikmat Abdel-Razeq

02:15pm – 02:30pm GS2-06. Phase Ib/II study evaluating safety and efficacy of pembrolizumab and trastuzumab in patients with trastuzumab-resistant HER2-positive metastatic breast cancer: Results from the PANACEA (IBCSG 45-13/KEYNOTE-014) study

Speaker: Prof./ Dr. Alaa Kandil

02:30pm – 02:45pm Adaptive phase II Randomized Non Comparative trial of Nivolumab  after induction treatment in Tripple –ve breast cancer ( First result of TONIC Trial)

Speaker: Dr. Adhar AlSayed

02:45pm – 03:00pm Updates in immuno-therapy in head and neck cancer

Speaker: Dr. Falah Alkhatib

03:00pm – 03:15pm Interaction between immuno-therapy and radiotherapy

Speaker: Dr. Yasser Bahadur

03:15PM

ABSTRACT FROM THE MIDDLE EAST

03:15PM - 03:45PM

Chairpersons: Dr. Ahmed Ali Saadeddin, Dr. Omalkhair Abulkhair, Prof. Jean-Marc Nabholtz, Dr. Lobna Sedky

03:00pm – 03:15pm Androgen receptor expression in estrogen receptor negative breast cancer

Speaker: Dr. Bilal Abusaida

03:30pm – 03:45pm  Impact of number of axillary lymph node dissected on survival in breast cancer patients

Speaker: Dr. Ahmed Maklad

03:45PM

Announcement of Abstract winners and Raffle draw

03:45PM - 03:55PM

03:55PM

CLOSING REMARKS 

03:55PM - 04:00PM

Register Now

Type 1

SAR

250

Consultants, Radiologists & Surgeons

Type 2

SAR

150

Non consultants & Nurses

Type 3

Free

Fellows, Medical Education & Patient Advocates

Registeration

Select your ticket type from the list below:

  • 12th Middle East Best of San Antonio Breast Cancer Symposium
    26 - 27 January 2018
  • Conference Place Address

    Le Méridien Medina
    Khaled Bin El Waleed Road, Medina Saudi Arabia

  • Send an Email

    donabelbigtas@dal-mark.com

  • Conference Coordinator

    Ms. Donabel V.Bigtas

  • Take a Look in Our Website

    www.mesabcs.com

  • +966 50 017 4313

This event brought to you by